Spinoff Redvax sold to Pfizer
Redbiotec has successfully developed a CMV vaccine program based on its rePAX® technology. This program was sold to Pfizer. See Pfizer press release, January 5 2014. Pfizer press release.
“Through the acquisition of the Redvax innovative CMV vaccine platform and expertise we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children,” said Kathrin U. Jansen, a senior vice president of Pfizer.
See also investor statement Redalpine blog.
Redbiotec celebrating 10th anniversary of its business
Redbiotec’s story started 10 years ago as spin-off company of the Swiss Federal Institute of Technology (ETH Zurich). In the heart of Redbiotec there has always been a continuous strong drive towards some of the biggest challenges in the healthcare sector. Over the past ten years it enabled pharma and biotech companies to have access to unique molecules. Redbiotec was among the first companies to mimic complex viruses with the de novo viral particle generation as vaccine candidates. Redbiotec also boosted the development of a highly needed vaccine against the Cytomegalovirus (CMV), being the first company to develop one of the key antigens.
Today Redbiotec has an ongoing promising program against Herpes simplex viruses and recently started applying its skills and experience to engineer microorganisms as diagnostic tools and therapies.
We would like to thank all our investors, clients, partners, advisors, suppliers - and especially acknowledge all our former and current employees.